Canada markets open in 1 hour 21 minutes
  • S&P/TSX

    20,985.37
    +57.27 (+0.27%)
     
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • DOW

    35,258.61
    -36.15 (-0.10%)
     
  • CAD/USD

    0.8102
    +0.0022 (+0.28%)
     
  • CRUDE OIL

    83.28
    +0.84 (+1.02%)
     
  • BTC-CAD

    76,832.69
    +1,178.66 (+1.56%)
     
  • CMC Crypto 200

    1,450.10
    -1.53 (-0.11%)
     
  • GOLD FUTURES

    1,781.10
    +15.40 (+0.87%)
     
  • RUSSELL 2000

    2,267.84
    +2.19 (+0.10%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,354.25
    +63.75 (+0.42%)
     
  • VOLATILITY

    16.00
    -0.30 (-1.84%)
     
  • FTSE

    7,207.66
    +3.83 (+0.05%)
     
  • NIKKEI 225

    29,215.52
    +190.06 (+0.65%)
     
  • CAD/EUR

    0.6947
    -0.0008 (-0.12%)
     

DEADLINE ALERT for SAVA, SPPI, LDI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BENSALEM, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

Cassava Sciences, Inc. (NASDAQ: SAVA)
Class Period: September 14, 2020 - August 27, 2021
Lead Plaintiff Deadline: October 26, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that data underlying the foundational research for Cassava’s product candidates had been manipulated; (2) that experiments using post-mortem human brain tissue frozen for nearly 10 years was contrary to a basic understanding of neurobiology; (3) that biomarker analysis for patients treated with simufilam had been manipulated to conclude that simufilam was effective; (4) that Quanterix, an independent company, had not interpreted the test results or prepared the data charts for the biomarker analysis for patients treated with simufilam; (5) that, as a result of the foregoing, there was a reasonable likelihood that Cassava would face regulatory scrutiny in connection with the development of simufilam; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Class Period: December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline: November 1, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (3) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

loanDepot, Inc. (NYSE: LDI)
IPO: February 16, 2021
Lead Plaintiff Deadline: November 8, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) loanDepot’s refinance originations had already declined substantially at the time of the IPO due to industry over-capacity and increased competition; (2) loanDepot’s gain-on-sale margins had already declined substantially at the time of the IPO; (3) as a result, loanDepot’s revenue and growth would be negatively impacted; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting